-
-
The FDA has approved a cfc-free levalbuterol aerosol inhaler for the treatment of asthma. Levalbuterol is the active isomer of albuterol and has been available in a nebulized solution for many years. This new formulation is marketed by Sepracor as Xopenex HFA.
-
A 6-year retrospective study shows that 45% of Medicare patients with state-funded drug benefits who initiate a medication for osteoporosis do not continue to take it as prescribed one year later and 52% are no longer compliant 5-years later.
-
-
-
Letrozole for Postmenopausal Women with Breast Cancer; Do Antidepressants Increase Risk of Suicide?; Can Viagra Improve Heart Function?; Can Tamoxifen Increase Your Height?; A Dramatic Increase of Clostridium difficile; FDA Actions
-
Prostate cancer is one of the leading causes of cancer in men, both in this country and in Europe. Recognizing that the primary care physician often is the first health care professional who determines whether a PSA test is ordered and often is crucial in directing further follow-up relating to diagnosis and treatment selection, Part II will deal with important information regarding the choices for treating prostate cancer, and the side effects, efficacy, and quality-of-life issues that result from treatment.
-
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.
-
Infliximab, an antibody against tumor necrosis factor, is effective in ulcerative colitis.